FDA approves neratinib/neratinib as an orphan drug for the treatment of breast cancer-related brain metastases

The U.S. Food and Drug Administration (FDA) recently approved neratinib/neratinib as an orphan drug for the treatment of brain metastases associated with breast cancer. This important approval provides new treatment options for breast cancer patients, especially those facing brain metastases. Brain metastatic breast cancer is a complex disease and its treatment often faces many challenges, so the FDA's decision is widely regarded as a positive development.

Neratinib is a tyrosine kinase inhibitor specifically designed to target human epidermal growth factor receptor 2 (HER2). Over the past few years, neratinib has been approved for long-term adjuvant treatment of patients with HER2-positive breast cancer, particularly after trastuzumab (Herceptin)-based adjuvant therapy. HER2 is a protein closely related to the development of breast cancer. Its overexpression usually indicates the aggressiveness of the disease and poor prognosis. Therefore, targeted therapy targeting HER2 has become the focus of research.

The FDA's approval of neratinib as an orphan drug means that it will receive special support in research and development, production and marketing to promote the development of drugs to treat rare diseases or diseases with unmet medical needs. The decision, which focuses specifically on patients suffering from HER2-positive breast cancer and its brain metastases, offers a new hope.

The phase II clinical study TBCRC 022 trial provides important data on the safety and efficacy of neratinib. In the study, 49 patients received 240 mg of neratinib and capecitabine at 750 mg/m² daily for 14 days, followed by 7 days off. The results showed that the combination was effective in treating brain metastases associated with HER2-positive breast cancer. The comprehensive central nervous system objective response rate was 49% (95% CI, 32-66) in lapatinib-naive patients and 33% (95% CI, 10-65) in lapatinib-experienced patients.

Further analysis found that the median progression-free survival of patients who had not received lapatinib was 5.5 months, while the median progression-free survival of patients who had received lapatinib was 3.1 months. As for median survival, it was 13.3 months for patients who did not receive lapatinib and 15.1 months for patients who had received treatment. These data demonstrate that the combination of neratinib and capecitabine can significantly improve survival and disease control in appropriate patients, especially in complex settings such as brain metastases.

Despite the remarkable efficacy of neratinib, adverse events have been observed in clinical studies. Diarrhea was the most common grade 3 adverse event, occurring in 29% of patients with or without prior lapatinib treatment. The occurrence of diarrhea may affect treatment compliance, so clinicians should closely monitor this side effect when treating patients with neratinib and take corresponding countermeasures, such as giving antidiarrheal drugs or adjusting the treatment plan.

Overall, neratinib, as a new tyrosine kinase inhibitor , provides patients with a new treatment option with its potential in treating brain metastasis of HER2-positive breast cancer. The FDA's approval not only provides researchers and clinicians with a richer range of treatments, but also brings hope to patients.

References:https://www.docwirenews.com/post/fda-grants-orphan-drug-designation-to-nerlynx-for-breast-cancer-related-brain-metastases